Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.

Article Details

Citation

Copy to clipboard

Klosiewicz-Latoszek L, Szostak WB

Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.

Eur J Clin Pharmacol. 1991;40(1):33-41.

PubMed ID

2060543 [ View in PubMed

]

Abstract

Two trials have been performed in the same patients with hyperlipoproteinaemia Types IIb (12 cases), III (6 cases) and IV (11 cases). In the first study the lipid-lowering properties of bezafibrate, fenofibrate, gemfibrozil, etofibrate and etofylline clofibrate were compared and in a separate trial the influence of combined treatment with gemfibrozil plus colestipol and bezafibrate plus probucol on lipoproteins were investigated. The mean percentage lipid-lowering effect of each fibrate on serum and VLDL fraction was significant in the Types IIb, III and IV patients, but there were significant differences between the fibrates. In general, gemfibrozil and bezafibrate decreased plasma lipid levels more than etofibrate and etofylline clofibrate in Type IIb patients. In Type IV cases gemfibrozil and bezafibrate were significantly potent in reducing the triglyceride level than fenofibrate, etofibrate or etofylline clofibrate. All the fibrates produced an increase in HDL cholesterol, but there were significant differences between them were in the Type IV patients. The influence of fibrates on the LDL fraction was much more variable. In hyperlipoproteinaemia Type IIb, a decrease in both LDL cholesterol and LDL apolipoprotein B was observed. In Type III and IV patients, however, an increase in LDL concentration occurred. The addition of colestipol to gemfibrozil therapy led to a further decrease in total cholesterol, LDL cholesterol and LDL apolipoprotein B in Type IIb patients. In patients with hyperlipoproteinaemia Types III and IV colestipol prevented the increase in LDL concentration after treatment with gemfibrozil alone. The effect of probucol on LDL cholesterol was comparable to that of colestipol. Combined treatment with gemfibrozil and colestipol caused an increase in HDL cholesterol concentration in contrast to combined treatment with bezafibrate and probucol.(ABSTRACT TRUNCATED AT 250 WORDS)

DrugBank Data that Cites this Article

Pharmaco-metabolomics

Drug	Drug Groups	Metabolite	Change	Description
Etofibrate	Experimental	Total cholesterol	decreased	Etofibrate decreases the level of Total cholesterol in the blood
Etofibrate	Experimental	VLDL triglycerides	decreased	Etofibrate decreases the level of VLDL triglycerides in the blood
Etofibrate	Experimental	VLDL cholesterol	decreased	Etofibrate decreases the level of VLDL cholesterol in the blood
Etofibrate	Experimental	LDL cholesterol	decreased	Etofibrate decreases the level of LDL cholesterol in the blood
Fenofibrate	Approved	Total cholesterol	decreased	Fenofibrate decreases the level of Total cholesterol in the blood
Gemfibrozil	Approved	Total cholesterol	decreased	Gemfibrozil decreases the level of Total cholesterol in the blood
Gemfibrozil	Approved	LDL cholesterol	decreased	Gemfibrozil decreases the level of LDL cholesterol in the blood
Bezafibrate	Approved Investigational	VLDL cholesterol	decreased	Bezafibrate decreases the level of VLDL cholesterol in the blood
Gemfibrozil	Approved	VLDL cholesterol	decreased	Gemfibrozil decreases the level of VLDL cholesterol in the blood
Fenofibrate	Approved	VLDL triglycerides	decreased	Fenofibrate decreases the level of VLDL triglycerides in the blood
Gemfibrozil	Approved	VLDL triglycerides	decreased	Gemfibrozil decreases the level of VLDL triglycerides in the blood
Bezafibrate	Approved Investigational	LDL cholesterol	decreased	Bezafibrate decreases the level of LDL cholesterol in the blood
Bezafibrate	Approved Investigational	VLDL triglycerides	decreased	Bezafibrate decreases the level of VLDL triglycerides in the blood
Bezafibrate	Approved Investigational	Total cholesterol	decreased	Bezafibrate decreases the level of Total cholesterol in the blood
Fenofibrate	Approved	HDL cholesterol	increased	Fenofibrate increases the level of HDL cholesterol in the blood
Etofibrate	Experimental	Triglycerides	decreased	Etofibrate decreases the level of Triglycerides in the blood
Fenofibrate	Approved	LDL cholesterol	decreased	Fenofibrate decreases the level of LDL cholesterol in the blood
Etofibrate	Experimental	HDL cholesterol	increased	Etofibrate increases the level of HDL cholesterol in the blood
Fenofibrate	Approved	VLDL cholesterol	decreased	Fenofibrate decreases the level of VLDL cholesterol in the blood